Processa Pharmaceuticals, Inc. (PCSA)Healthcare | Biotechnology | Vero Beach, United States | NasdaqCM
2.06 USD
-0.13
(-5.936%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.08 +0.02 (0.971%) ⇧ (July 13, 2026, 4:19 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:34 a.m. EDT
The immediate outlook remains deeply bearish due to a catastrophic multi-year price collapse. The stock has lost 99.93% of its value over the last nine years, with four consecutive years of negative annual returns ending recently. While insider buying by the CEO and CFO provides a glimmer of confidence that management believes in the underlying science, this cannot offset the structural reality that the market has priced out the company entirely. The recent surge appears to be a volatile reaction to clinical data rather than a sustainable trend, especially given the severe technical weakness relative to moving averages. Fundamentally, the company is in distress with negative earnings, negative free cash flow, and a current ratio below 1.0, indicating liquidity strain. With no dividend history and a forward P/E that is meaningless due to losses, there is no margin of safety here. This is a speculative gamble on a potential turnaround, not an investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.172442 |
| AutoETS | 0.172446 |
| MSTL | 0.180700 |
| AutoTheta | 0.233783 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 22.75 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.167 |
| Excess Kurtosis | -1.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 5,702,146 |
| Forward P/E | -0.55 |
| Beta | 0.99 |
| Website | https://www.processapharmaceuticals.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5962617 |
| Address1 | 601 21st Street |
| Address2 | Suite 300 |
| All Time High | 67,375.0 |
| All Time Low | 1.67 |
| Ask | 1.91 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 68,590 |
| Average Daily Volume3 Month | 65,045 |
| Average Volume | 65,045 |
| Average Volume10Days | 68,590 |
| Beta | 0.986 |
| Bid | 2.18 |
| Bid Size | 1 |
| Book Value | 0.949 |
| City | Vero Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.06 |
| Current Ratio | 0.979 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.16 |
| Day Low | 2.05 |
| Display Name | Processa Pharmaceuticals |
| Dividend Date | 1,577,059,200 |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda | -14,471,525 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.275 |
| Enterprise Value | 3,974,313 |
| Eps Forward | -3.75 |
| Eps Trailing Twelve Months | -4.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 443 288 4420 |
| Fifty Day Average | 2.3906 |
| Fifty Day Average Change | -0.33060002 |
| Fifty Day Average Change Percent | -0.13829166 |
| Fifty Two Week Change Percent | -59.626167 |
| Fifty Two Week High | 14.25 |
| Fifty Two Week High Change | -12.190001 |
| Fifty Two Week High Change Percent | -0.85543865 |
| Fifty Two Week Low | 1.67 |
| Fifty Two Week Low Change | 0.39 |
| Fifty Two Week Low Change Percent | 0.23353294 |
| Fifty Two Week Range | 1.67 - 14.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,394,202,600,000 |
| Float Shares | 2,643,274 |
| Forward Eps | -3.75 |
| Forward P E | -0.54933333 |
| Free Cashflow | -6,958,213 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14901 |
| Held Percent Institutions | 0.10241 |
| Implied Shares Outstanding | 2,768,032 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,765,929,600 |
| Last Split Factor | 1:25 |
| Long Business Summary | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida. |
| Long Name | Processa Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 5,702,146 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_531045531 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -14,106,608 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,978,949 |
| Open | 2.12 |
| Operating Cashflow | -12,246,042 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 772 453 2899 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.9708729 |
| Post Market Price | 2.08 |
| Post Market Time | 1,783,973,950 |
| Previous Close | 2.19 |
| Price Hint | 4 |
| Price To Book | 2.170706 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.854 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.13 |
| Regular Market Change Percent | -5.93608 |
| Regular Market Day High | 2.16 |
| Regular Market Day Low | 2.05 |
| Regular Market Day Range | 2.05 - 2.16 |
| Regular Market Open | 2.12 |
| Regular Market Previous Close | 2.19 |
| Regular Market Price | 2.06 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 25,288 |
| Return On Assets | -1.9388901 |
| Return On Equity | -4.6499 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,768,032 |
| Shares Percent Shares Out | 0.0311 |
| Shares Short | 86,054 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 91,063 |
| Short Name | Processa Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0363 |
| Short Ratio | 1.36 |
| Source Interval | 15 |
| State | FL |
| Symbol | PCSA |
| Total Cash | 1,691,043 |
| Total Cash Per Share | 0.615 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.09409 |
| Two Hundred Day Average Change | -2.03409 |
| Two Hundred Day Average Change Percent | -0.4968357 |
| Type Disp | Equity |
| Volume | 25,288 |
| Website | https://www.processapharmaceuticals.com |
| Zip | 32,960 |